apatinib

Jiangsu Hengrui Pharmaceuticals is a leading global pharmaceutical company headquartered in Lianyungang, China, specializing in the development of innovative oncology, metabolic, and autoimmune therapies. The company is the originator of apatinib (Aitan), a highly selective VEGFR2 tyrosine kinase inhibitor approved for gastric and hepatocellular cancers. Hengrui has successfully transitioned from a generic manufacturer to an innovation-led biopharma, boasting a robust pipeline of small molecules, monoclonal antibodies, and antibody-drug conjugates. With multiple products commercialized in China and several undergoing global clinical trials, the company remains a dominant force in the Chinese healthcare market while expanding its footprint in the United States and Europe.